Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) revealed earnings for full year that Dropped, from the same period last year
The company's bottom line came in at RMB1.777 billion, or RMB1.93 per share. This compares with RMB2.531 billion, or RMB2.76 per share, last year.
The company's revenue for the period fell 22.4% to RMB6.218 billion from RMB8.016 billion last year.
Hubei Jumpcan Pharmaceutical Co., Ltd. earnings at a glance (GAAP) :
-Earnings: RMB1.777 Bln. vs. RMB2.531 Bln. last year.-EPS: RMB1.93 vs. RMB2.76 last year.-Revenue: RMB6.218 Bln vs. RMB8.016 Bln last year.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.